Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Renu Chaudhary, Bharat Singh, Manish Kumar, Surendra K. Gakhar, Adesh K. Saini, Virinder S. Parmar & Anil K. Chhillar. (2015) Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. Drug Metabolism Reviews 47:3, pages 281-290.
Read now
Read now
Soma Ghosh, Jordan M. Winter, Kalpesh Patel & Scott E. Kern. (2011) Reexamining a proposal. Cancer Biology & Therapy 12:8, pages 750-755.
Read now
Read now
Lawrence Leichman, Cynthia Gail Leichman. (2001) Therapy of Disseminated Colorectal Cancer: The Emerging Role of Intratumoral Molecular Biology. The European Journal of Surgery 167:586, pages 43-48.
Read now
Read now
Lalitha lyer & Mark J. Ratain. (1999) 5-Fluorouracil Pharmacokinetics: Causes for Variability and Strategies for Modulation in Cancer Chemotherapy. Cancer Investigation 17:7, pages 494-506.
Read now
Read now
Articles from other publishers (44)
Iffath Ahmed, HamdanIftikhar Siddiqui, GhaniaShehzad Qureshi & GrisildaVidya Bernhardt. (2022) A review of literature on the pharmacogenomics of single-nucleotide polymorphisms. Biomedical and Biotechnology Research Journal (BBRJ) 6:1, pages 14.
Crossref
Crossref
Azher Arafah, Shafat Ali, Sabhiya Majid, Samia Rashid, Shabhat Rasool, Hilal Ahmad Wani, Iyman Rasool & Muneeb U. Rehman. 2021. Genetic Polymorphism and cancer susceptibility. Genetic Polymorphism and cancer susceptibility
23
52
.
Marina Borro, Andrea Botticelli, Federica Mazzuca, Elisa Concetta Onesti, Giovanna Gentile, Adriana Romiti, Bruna Cerbelli, Eva Mazzotti, Luca Marchetti, Luana Lionetto, Maurizio Simmaco & Paolo Marchetti. (2016) Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. Oncotarget 8:8, pages 14050-14057.
Crossref
Crossref
G Gentile, A Botticelli, L Lionetto, F Mazzuca, M Simmaco, P Marchetti & M Borro. (2015) Genotype–phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. The Pharmacogenomics Journal 16:4, pages 320-325.
Crossref
Crossref
A. Ducournau, P. Lagarde, B. Henriques de Figueiredo, M. Antoine, C. Breton-Callu, A. Petit, B. Dallaudière & P. Sargos. (2014) Radiothérapie chez une patiente atteinte d’un cancer du sein et d’ostéogenèse imparfaite : à propos d’un cas. Cancer/Radiothérapie 18:2, pages 132-135.
Crossref
Crossref
Miriam López-Gómez, Paloma Cejas, María Merino, David Fernández-Luengas, Enrique Casado & Jaime Feliu. (2012) Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?. Clinical and Translational Oncology 14:9, pages 641-658.
Crossref
Crossref
Soma Ghosh, M. Zulfiquer Hossain, Michael Borges, Michael G. Goggins, Roxann G. Ingersoll, James R. Eshleman, Alison P. Klein & Scott E. Kern. (2012) Analysis of Polymorphisms and Haplotype Structure of the Human Thymidylate Synthase Genetic Region: A Tool for Pharmacogenetic Studies. PLoS ONE 7:4, pages e34426.
Crossref
Crossref
K. F. Newton, W. Newman & J. Hill. (2012) Review of biomarkers in colorectal cancer. Colorectal Disease 14:1, pages 3-17.
Crossref
Crossref
C.S. Boskos, C. Liacos, D. Korkolis, K. Aygerinos, I. Lamproglou, E. Terpos, E. Stoupa, G. Baltatzis, K. Beroukas, P. Papasavvas, M.A. Dimopoulos & A. Bamias. (2010) Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. Journal of Surgical Oncology 102:5, pages 408-412.
Crossref
Crossref
Takayuki Shibata, Shin-ya Kawasaki, Jun-ya Fujita, Tsutomu Kabashima & Masaaki Kai. (2010) A novel and specific fluorescence reaction for uracil. Analytica Chimica Acta 674:2, pages 234-238.
Crossref
Crossref
Roberta Ferraldeschi. 2010. Pharmacogenetics: Making cancer treatment safer and more effective. Pharmacogenetics: Making cancer treatment safer and more effective
61
86
.
Jonathan R. Brody, Tomas Hucl, Christina L. Costantino, James R. Eshleman, Eike Gallmeier, Heng Zhu, Michiel S. van der Heijden, Jordan M. Winter, Agnieszka K. Wikiewicz, Charles J. Yeo & Scott E. Kern. (2009)
Limits to Thymidylate Synthase and
TP53
Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence
. Cancer Research 69:3, pages 984-991.
Crossref
Crossref
Joseph Ciccolini, Cédric Mercier & Gérard Milano. 2009. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
249
265
.
E. Casado, J. De Castro, C. Belda-Iniesta, P. Cejas, J. Feliu, M. Sereno & M. González-Barón. (2007) Molecular markers in colorectal cancer: genetic bases for a customised treatment. Clinical and Translational Oncology 9:9, pages 549-554.
Crossref
Crossref
Daniel B Longley, Wendy L. Allen & Patrick G. Johnston. (2006) Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1766:2, pages 184-196.
Crossref
Crossref
Cédric Mercier & Joseph Ciccolini. (2006) Profiling Dihydropyrimidine Dehydrogenase Deficiency in Patients with Cancer Undergoing 5-Fluorouracil/Capecitabine Therapy. Clinical Colorectal Cancer 6:4, pages 288-296.
Crossref
Crossref
Sharon J. Gardiner & Evan J. Begg. (2006) Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. Pharmacological Reviews 58:3, pages 521-590.
Crossref
Crossref
Wei Peng Yong, Federico Innocenti & Mark J. Ratain. (2006) The role of pharmacogenetics in cancer therapeutics. British Journal of Clinical Pharmacology 62:1, pages 35-46.
Crossref
Crossref
Su-arpa Ploylearmsaeng, Uwe Fuhr & Alexander Jetter. (2006) How may Anticancer Chemotherapy with Fluorouracil be Individualised?. Clinical Pharmacokinetics 45:6, pages 567-592.
Crossref
Crossref
Makoto INADA, Takefumi SHIMIZU & Nobuhiro IKEI. (2006) Determination of Dihydropyrimidine Dehydrogenase Activity in Human Peripheral Blood Mononuclear Cells by Radio-HPLC Method. BUNSEKI KAGAKU 55:1, pages 45-49.
Crossref
Crossref
Suminobu Ito, Takeshi Kawamura, Makoto Inada, Yoshiharu Inoue, Yukihiro Hirao, Toshihisa Koga, Jun‐ichi Kunizaki, Takefumi Shimizu & Hitoshi Sato. (2005)
Physiologically based pharmacokinetic modelling of the three‐step metabolism of pyrimidine using
13
C‐uracil as an
in vivo
probe
. British Journal of Clinical Pharmacology 60:6, pages 584-593.
Crossref
Crossref
Makoto Inada, Yukihiro Hirao, Toshihisa Koga, Minoru Itose, Jun-ichi Kunizaki, Takefumi Shimizu & Hitoshi Sato. (2005)
RELATIONSHIPS AMONG PLASMA [2-
13
C]URACIL CONCENTRATIONS, BREATH
13
CO
2
EXPIRATION, AND DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) ACTIVITY IN THE LIVER IN NORMAL AND DPD-DEFICIENT DOGS
. Drug Metabolism and Disposition 33:3, pages 381-387.
Crossref
Crossref
Mika Endo, Masanori Miwa, Hiroyuki Eda, Masako Ura, Hiromi Tanimura, Tohru Ishikawa, Taeko Miyazaki-Nose, Kazuo Hattori, Nobuo Shimma, Hisafumi Yamada-Okabe & Hideo Ishitsuka. (2003) Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. International Journal of Cancer 106:5, pages 799-805.
Crossref
Crossref
Daniel B. Longley, Ultan McDermott & Patrick G. Johnston. (2003) Predictive Markers for Colorectal Cancer: Current Status and Future Prospects. Clinical Colorectal Cancer 2:4, pages 223-230.
Crossref
Crossref
D B Longley, U McDermott & P G Johnston. (2002) Clinical significance of prognostic and predictive markers in colorectal cancer. The Pharmacogenomics Journal 2:4, pages 209-216.
Crossref
Crossref
Sharon J. Gardiner, Evan J. Begg & Bridget A. Robinson. (2012) The Effect of Dihydropyrimidine Dehydrogenase Deficiency on Outcomes with Fluorouracil. Adverse Drug Reactions and Toxicological Reviews 21:1-2, pages 1-16.
Crossref
Crossref
Naoko Takebe, Shi-Cheng Zhao, Ali U Ural, Martin R Johnson, Debabrata Banerjee, Robert B Diasio & Joseph R Bertino. (2001) Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Therapy 8:12, pages 966-973.
Crossref
Crossref
Syma Iqbal & Heinz-Josef Lenz. (2001) Determinants of prognosis and response to therapy in colorectal cancer. Current Oncology Reports 3:2, pages 102-108.
Crossref
Crossref
John G Kuhn. (2016) Fluorouracil and the New Oral Fluorinated Pyrimidines. Annals of Pharmacotherapy 35:2, pages 217-227.
Crossref
Crossref
Federico Innocenti, Lalitha Iyer & Mark J. Ratain. (2000) Pharmacogenetics. Clinical Pharmacokinetics 39:5, pages 315-325.
Crossref
Crossref
Masami Asai, Satoshi Sumi, Kiyoshi Kidouchi, Hiromi Imaeda, Hajime Togari & Yoshiro Wada. (2000) Urinary pyrimidine analysis in healthy newborns, infants, children, adults and patients with congenital metabolic diseases. Pediatrics International 42:5, pages 499-503.
Crossref
Crossref
Tohru Maeda, Satoshi Sumi, Katsuo Hayashi, Kiyoshi Kidouchi, Tadashi Owaki, Hajime Togari, Shinji Fujimoto & Yoshiro Wada. (1999) Automated determination of 5-fluorouracil and its metabolite in urine by high-performance liquid chromatography with column switching. Journal of Chromatography B: Biomedical Sciences and Applications 731:2, pages 267-273.
Crossref
Crossref
A B P Van Kuilenburg, H van Lenthe, M J Blom, E P J Mul & A H Van Gennip. (1999) Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. British Journal of Cancer 79:3-4, pages 620-626.
Crossref
Crossref
L. Iyer & M.J. Ratain. (1998) Pharmacogenetics and cancer chemotherapy. European Journal of Cancer 34:10, pages 1493-1499.
Crossref
Crossref
A.B.P. Van Kuilenburg, P. Vreken, L.V.A.M. Beex, R. Meinsma, H. Van Lenthe, R.A. De Abreu & A.H. Van Gennip. (1997) Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. European Journal of Cancer 33:13, pages 2258-2264.
Crossref
Crossref
Martin R. Johnson, Jieming Yan, Lingning Shao, Nicolas Albin & Robert B. Diasio. (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. Journal of Chromatography B: Biomedical Sciences and Applications 696:2, pages 183-191.
Crossref
Crossref
Corey J. Langer. (2012) Dihydropyrimidine Dehydrogenase Deficiency: A Potential Etiology for 5‐Fluorouracil‐Induced Neurotoxicity—Author's Reply. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17:4, pages 849-849.
Crossref
Crossref
P. Beuzeboc, J.-Y. Pierga, D. Stoppa-Lyonnet, M.C. Etienne, G. Milano & P. Fouillait. (1996) Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta. European Journal of Cancer 32:2, pages 369-370.
Crossref
Crossref
Zhihong Lu, Ruiwen Zhang & Robert B. Diasio. (1995) Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*. Clinical Pharmacology & Therapeutics 58:5, pages 512-522.
Crossref
Crossref
Satoshi Sumi, Kiyoshi Kidouchi, Satoru Ohba & Yoshiro Wada. (1995) Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 672:2, pages 233-239.
Crossref
Crossref
R. MEINSMA, P. FERNANDEZ-SALGUERO, A.B.P. VAN KUILENBURG, A.H. VAN GENNIP & F.J. GONZALEZ. (1995) Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Results in Exon Skipping and Thymine Uracilurea. DNA and Cell Biology 14:1, pages 1-6.
Crossref
Crossref
R. B. Diasio, A. B. P. Van Kuilenburg, Z. Lu, R. Zhang, H. Van Lenthe, H. D. Bakker & A. H. Van Gennip. 1994. Purine and Pyrimidine Metabolism in Man VIII. Purine and Pyrimidine Metabolism in Man VIII
7
10
.
Robert B. Diasio, Zhihong Lu, Ruiwen Zhang & Harout S. Shahinian. 1995. Concepts, Mechanisms, and New Targets for Chemotherapy. Concepts, Mechanisms, and New Targets for Chemotherapy
71
93
.
H. Yokota, P. Fernandez-Salguero, H. Furuya, K. Lin, O.W. McBride, B. Podschun, K.D. Schnackerz & F.J. Gonzalez. (1994) cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria.. Journal of Biological Chemistry 269:37, pages 23192-23196.
Crossref
Crossref